Pre-Made Efanesoctocog Alfa Biosimilar, Fusion Protein targeting F8 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AHF/F8B/F8C/HEMA/FVIII/DXS1253E for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Efanesoctocog Alfa Biosimilar, Fusion Protein targeting F8 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AHF/F8B/F8C/HEMA/FVIII/DXS1253E is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Efanesoctocog alfa is an investigational and longer-lasting factor VIII (FVIII) replacement therapy for people with hemophilia A. Efanesoctocog alfa is based on Fc fusion technology, and is made by adding a region of a blood-clotting protein called von Willebrand factor (VWF) and a polypeptide called XTEN to a recombinant, or man-made, FVIII-Fc fusion protein
| Products Name (INN Index) | Pre-Made Efanesoctocog Alfa Biosimilar, Fusion Protein targeting F8 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AHF/F8B/F8C/HEMA/FVIII/DXS1253E |
|---|---|
| INN Name | efanesoctocog alfa |
| Target | F8 |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – F8 (coagulation factor VIII) with deleted B- domain – VWF (von Willebrand factor) – XTEN – IGHG1 Fc (Fragment constant) |
| VD LC | Fusion – F8 (coagulation factor VIII) with deleted B- domain – VWF (von Willebrand factor) – XTEN – IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Biogen,?Inc. (Cambridge MA USA) / Amunix (Moutain View CA USA) / Bioverativ, Inc. (Waltham MA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | F8 |
| Package |
